Biorestorative Therapies (NASDAQ:BRTX – Get Free Report) and Invivyd (NASDAQ:IVVD – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Biorestorative Therapies and Invivyd, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biorestorative Therapies | 1 | 0 | 0 | 0 | 1.00 |
| Invivyd | 1 | 2 | 3 | 0 | 2.33 |
Invivyd has a consensus target price of $8.00, suggesting a potential upside of 959.18%. Given Invivyd’s stronger consensus rating and higher possible upside, analysts clearly believe Invivyd is more favorable than Biorestorative Therapies.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Biorestorative Therapies | -3,088.27% | -508.42% | -230.94% |
| Invivyd | -183.90% | -59.73% | -48.97% |
Institutional and Insider Ownership
69.4% of Biorestorative Therapies shares are owned by institutional investors. Comparatively, 70.4% of Invivyd shares are owned by institutional investors. 13.6% of Biorestorative Therapies shares are owned by company insiders. Comparatively, 12.2% of Invivyd shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
Biorestorative Therapies has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Invivyd has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500.
Valuation and Earnings
This table compares Biorestorative Therapies and Invivyd”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biorestorative Therapies | $360,000.00 | 10.31 | -$14.24 million | ($21.40) | -0.13 |
| Invivyd | $53.43 million | 4.17 | -$52.49 million | ($0.33) | -2.29 |
Biorestorative Therapies has higher earnings, but lower revenue than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.
Summary
Invivyd beats Biorestorative Therapies on 9 of the 14 factors compared between the two stocks.
About Biorestorative Therapies
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.
About Invivyd
Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Biorestorative Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biorestorative Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
